Bayer Aktiengesellschaft (BUD:BAYER)
Hungary · Delayed Price · Currency is HUF | Market Cap | 12.35T +26.3% |
| Revenue (ttm) | 17.46T -2.9% |
| Net Income | -832.11B |
| EPS | -847.00 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 7.94 |
| Dividend | 40.15 (0.32%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 15 |
| Open | 12,580 |
| Previous Close | 12,750 |
| Day's Range | 12,580 - 12,580 |
| 52-Week Range | 10,000 - 18,700 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Bayer hopes to speed up biofuel feedstock plan amid Iran war energy crunch
Bayer is hoping to speed up a plan to facilitate North American production of biofuel feedstocks like camelina in the wake of the Iran war, the drug-making and crop science giant said on Wednesday.
Bayer appoints Reinhard as President of the Radiology business
Bayer (BAYRY) announced that Dr. Jost Reinhard has been appointed President of the Radiology business within Bayer’s Pharmaceuticals Division, effective August 1, 2026. In his new capacity, he will re...
Dr. Jost Reinhard Appointed President of Bayer's Radiology Business
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that Dr. Jost Reinhard has been appointed President of the Radiology business within Bayer's Pharmaceuticals Division, effective August 1, 2026. ...
Bayer announces leadership changes within Consumer Health division
Bayer (BAYRY) announced leadership changes within its Consumer Health division. Key leadership appointments include: Samantha Avivi appointed global Chief Marketing Officer, Consumer Health; Analia de...
Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth
BASEL, Switzerland & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced leadership changes within its Consumer Health division to accelerate growth, strengthen commercial execution, and further en...
Bayer says Kerendia met primary endpoint in Phase III FIND-CKD trial
Bayer (BAYRY) announced full results from the Phase III FIND-CKD trial investigating Kerendia in adults with non-diabetic chronic kidney disease who were also receiving background standard of care. In...
Phase III FIND‑CKD Results Show Bayer's KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today full results from the Phase III FIND-CKD trial investigating KERENDIA® (finerenone) in adults with non-diabetic chronic kidney dise...
Bayer says no plans to restructure despite litigation threat
Bayer has no plans to spin off Monsanto, a representative said on Tuesday, even as the company faces an avalanche of lawsuits over its Roundup weedkiller.
Bayer announces new investigational data from Kerendia’s Phase III trial
Bayer (BAYRY) announced that new investigational data from Kerendia’s Phase III clinical trial program will be presented in scientific sessions at the 63rd European Renal Association, ERA, Congress ta...
Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that new investigational data from KERENDIA's Phase III clinical trial program will be presented in scientific sessions at the 63rd...
ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
WHIPPANY, N.J.--(BUSINESS WIRE)--Primary results from the Phase II ARACOG (AFT-47) trial, a head-to-head randomized trial conducted by Alliance Foundation Trials LLC, showed that patients treated with...
Bayer assumed with a Hold at Jefferies
Jefferies analyst Michael Leuchten assumed coverage of Bayer (BAYRY) with a Hold rating and a price target of EUR 40, up from EUR 25. Litigation resolution remains the main pivot,…
Bayer sued for allegedly monopolizing US market for GMO corn seeds
Bayer used illegal and anti-competitive practices to monopolize the U.S. market for genetically engineered corn seeds, reaping "hundreds of millions, if not billions, of ill-gotten dollars," accordin...
Olema Oncology announces collaboration, supply agreement with Bayer
Olema Pharmaceuticals announced a clinical trial collaboration and supply agreement with Bayer AG (BAYRY) to evaluate OP-3136, Olema’s investigational lysine acetyltransferase 6 inhibitor, in combinat...
Bayer to present new data across oncology portfolio
Bayer (BAYRY) announced that new data from studies across their oncology portfolio will be presented at the upcoming 2026 American Society of Clinical Oncology, ASCO, Annual Meeting, taking place in…
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
WHIPPANY, N.J.--(BUSINESS WIRE)--ASCO 2026: Bayer to Present New Data Across Oncology Portfolio.
Bayer announces Priority Review designation for Kerendia
Bayer (BAYRY) announced that the FDA accepted its supplemental new drug application and granted Priority Review designation for Kerendia, which is being investigated for the treatment of adults with t...
Bayer says FDA grants priority review designation for finerenone
Bayer said on Thursday that the U.S. Food and Drug Administration had accepted its supplemental New Drug Application for finerenone and granted priority review designation.
Bayer's KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) and granted Priority Review ...
Bayer Aktiengesellschaft Slides: Corporate presentation
Bayer Aktiengesellschaft has posted slides in relation to its latest quarterly earnings report, which was published on May 21, 2026.
Bayer upgraded to Buy from Hold at DZ Bank
DZ Bank upgraded Bayer (BAYRY) to Buy from Hold with a EUR 51 price target
Bayer granted priority review for asundexian by FDA
Bayer (BAYRY) announced that the FDA has accepted the company’s new drug application and granted priority review designation for its investigational oral Factor XIa inhibitor, asundexian, for the prev...
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer: WHAT'S HAPPENING Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) and granted Priori...
Bayer agrees to pay $133 million for PCB cleanup in two states
Bayer's Monsanto unit on Monday said it would pay at least $133 million to settle Michigan and Rhode Island's claims that the company contaminated the states' natural resources with toxic chemicals ...
Bayer announces HYRNUO sNDA granted Priority Review status by FDA
Bayer (BAYRY) announced that the U.S. Food and Drug Administration has granted HYRNUO Priority Review status for the first-line treatment of adult patients with locally advanced or metastatic non-smal...